Nothing Special   »   [go: up one dir, main page]

SK6212003A3 - Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia - Google Patents

Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia Download PDF

Info

Publication number
SK6212003A3
SK6212003A3 SK621-2003A SK6212003A SK6212003A3 SK 6212003 A3 SK6212003 A3 SK 6212003A3 SK 6212003 A SK6212003 A SK 6212003A SK 6212003 A3 SK6212003 A3 SK 6212003A3
Authority
SK
Slovakia
Prior art keywords
ldl
patient
patients
cholesterol
methylsulfonyl
Prior art date
Application number
SK621-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Ali Raza
Howard Gerard Hutchinson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK6212003(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SK6212003A3 publication Critical patent/SK6212003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK621-2003A 2000-11-22 2001-11-16 Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia SK6212003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
PCT/GB2001/005041 WO2002041895A1 (fr) 2000-11-22 2001-11-16 Utilisation de la rosuvastatine (zd-4522) dans le traitement de l'hypercholesterolemie familiale

Publications (1)

Publication Number Publication Date
SK6212003A3 true SK6212003A3 (en) 2003-11-04

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
SK621-2003A SK6212003A3 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia

Country Status (35)

Country Link
US (1) US6858618B2 (fr)
EP (1) EP1339409B1 (fr)
JP (2) JP5062940B2 (fr)
KR (1) KR100815042B1 (fr)
CN (1) CN1268339C (fr)
AR (1) AR031766A1 (fr)
AT (1) ATE394103T1 (fr)
AU (2) AU2002214165B9 (fr)
BG (1) BG66009B1 (fr)
BR (1) BR0115511A (fr)
CA (1) CA2429263C (fr)
CY (1) CY1110428T1 (fr)
CZ (1) CZ301583B6 (fr)
DE (1) DE60133921D1 (fr)
DK (1) DK1339409T3 (fr)
EE (1) EE05507B1 (fr)
ES (1) ES2305118T3 (fr)
GB (1) GB0028429D0 (fr)
HK (1) HK1056691A1 (fr)
HU (1) HUP0301380A3 (fr)
IL (2) IL155919A0 (fr)
IS (1) IS6819A (fr)
MX (1) MXPA03004336A (fr)
MY (1) MY134902A (fr)
NO (1) NO326245B1 (fr)
NZ (1) NZ525754A (fr)
PL (1) PL365386A1 (fr)
PT (1) PT1339409E (fr)
RU (1) RU2294744C2 (fr)
SI (1) SI1339409T1 (fr)
SK (1) SK6212003A3 (fr)
TW (1) TWI238720B (fr)
UA (1) UA75614C2 (fr)
WO (1) WO2002041895A1 (fr)
ZA (1) ZA200303636B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
CA2522845A1 (fr) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues de phosphonate inhibiteurs de kinase
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
JP5069463B2 (ja) * 2003-04-25 2012-11-07 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス性ホスホネート類似物
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7396927B2 (en) * 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005051921A1 (fr) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Sels d'ammonium cristallins de la rosuvastatine
CA2546894C (fr) * 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Norme de reference pour la caracterisation de la rosuvastatine
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
AU2005247160A1 (en) * 2004-05-26 2005-12-08 Kgk Synergize Inc Functional foods comprising flavonoids and tocotrienols and methods thereof
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
PL1778251T3 (pl) 2004-07-27 2011-09-30 Gilead Sciences Inc Koniugaty fosfonianowo-nukleozydowe jako środki przeciw wirusowi HIV
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US7612203B2 (en) * 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
JP2008515931A (ja) * 2005-08-16 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 結晶形ロスバスタチン中間体
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
CA2725052C (fr) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Procede de preparation de la rosuvastatine calcique et de ses intermediaires
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
CA3111317C (fr) 2012-09-17 2023-08-29 F. Hoffmann-La Roche Ltd. Procede de synthese d'analogues de l'hormone thyroidienne et de ses polymorphes
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
BR112021023782A2 (pt) 2019-05-27 2022-01-11 Immatics Us Inc Vetores, métodos de preparação de células t para imunoterapia, populações de células t expandidas e métodos para tratar de um paciente com câncer e para elicitar uma resposta imune
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2022040631A1 (fr) 2020-08-21 2022-02-24 Immatics US, Inc. Procédés d'isolement de lymphocytes t sélectionnés cd8+
CN116847847A (zh) * 2021-02-01 2023-10-03 马德里加尔制药公司 用于治疗肝紊乱或血脂紊乱的瑞舒伐他汀和resmetirom的治疗组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
DE60129573T2 (de) * 2000-09-20 2008-04-17 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat

Also Published As

Publication number Publication date
EE05507B1 (et) 2012-02-15
EP1339409B1 (fr) 2008-05-07
IL155919A (en) 2009-09-01
CZ301583B6 (cs) 2010-04-21
AR031766A1 (es) 2003-10-01
NO20032292L (no) 2003-07-17
TWI238720B (en) 2005-09-01
ATE394103T1 (de) 2008-05-15
NO20032292D0 (no) 2003-05-21
KR20030048479A (ko) 2003-06-19
PL365386A1 (en) 2005-01-10
AU1416502A (en) 2002-06-03
SI1339409T1 (sl) 2008-08-31
DK1339409T3 (da) 2008-09-08
HUP0301380A3 (en) 2007-03-28
CA2429263A1 (fr) 2002-05-30
PT1339409E (pt) 2008-07-07
ZA200303636B (en) 2004-08-12
CN1268339C (zh) 2006-08-09
ES2305118T3 (es) 2008-11-01
US20040072852A1 (en) 2004-04-15
CY1110428T1 (el) 2015-04-29
AU2002214165B9 (en) 2013-07-04
BG107811A (bg) 2004-03-31
GB0028429D0 (en) 2001-01-10
RU2294744C2 (ru) 2007-03-10
MXPA03004336A (es) 2003-08-19
KR100815042B1 (ko) 2008-03-18
BR0115511A (pt) 2003-12-30
CZ20031406A3 (cs) 2003-09-17
NO326245B1 (no) 2008-10-27
NZ525754A (en) 2004-10-29
HK1056691A1 (en) 2004-02-27
JP2004522714A (ja) 2004-07-29
HUP0301380A2 (hu) 2003-10-28
JP2010031047A (ja) 2010-02-12
UA75614C2 (uk) 2006-05-15
CA2429263C (fr) 2009-03-17
WO2002041895A1 (fr) 2002-05-30
MY134902A (en) 2007-12-31
DE60133921D1 (de) 2008-06-19
JP5062940B2 (ja) 2012-10-31
AU2002214165B2 (en) 2006-12-14
BG66009B1 (bg) 2010-10-29
IL155919A0 (en) 2003-12-23
IS6819A (is) 2003-05-19
US6858618B2 (en) 2005-02-22
EP1339409A1 (fr) 2003-09-03
CN1630520A (zh) 2005-06-22
EE200300239A (et) 2003-08-15

Similar Documents

Publication Publication Date Title
SK6212003A3 (en) Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia
AU2002214165A1 (en) Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia
US5260305A (en) Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
JP2014065718A (ja) 糖尿病性神経障害の治療用医薬品を製造するための３−ヒドロキシ−３−メチルグルタリル補酵素ａレダクターゼ阻害剤の使用
JP2011137023A (ja) コレステロール低下薬の使用
US20040192784A1 (en) Combination of a betablocker and a cholesterol-lowering agent
US20040087597A1 (en) Preventives and remedies for complications of diabetes
US20070197602A1 (en) Combined pharmaceutical composition
NZ501844A (en) Alkanoyl L-carnitine in combination with a statin (simvastatin, lovastatin, provastatin or fluvastatin) for treating abnormal lipid metabolism disorders
JP4409295B2 (ja) Ｐｔｘ３遺伝子発現抑制方法
JP4187141B2 (ja) 新規なトロンボモジュリン発現促進剤
EP1296716B1 (fr) Utilisation d'un beta-bloquant pour le traitement de l'atherosclerose
Shimpi et al. Bempedoic acid a novel drug used for the treatment of Hyperlipidaemia: A Review
WO2002020009A1 (fr) Compositions medicales
MXPA99011665A (en) Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

Legal Events

Date Code Title Description
FC9A Refused patent application